Doximity, Inc.

NYSE:DOCS 株式レポート

時価総額：US$4.4b

Doximity 過去の業績

過去 基準チェック /26

Doximityは、平均年間20.6%の収益成長を遂げていますが、 Healthcare Services業界の収益は、年間 成長しています。収益は、平均年間21.6% 16.9%収益成長率で 成長しています。 Doximityの自己資本利益率は18.2%であり、純利益率は25.5%です。

主要情報

20.58%

収益成長率

16.03%

EPS成長率

Healthcare Services 業界の成長1.72%
収益成長率16.90%
株主資本利益率18.24%
ネット・マージン25.48%
前回の決算情報30 Jun 2026

最近の業績更新

Recent updates

ナラティブ更新 • Aug 08

DOCS: AI Investment Year And Pharma Budget Share Will Shape Fairly Valued Outlook

Analysts have raised Doximity’s fair value estimate from $24.37 to $28.00, reflecting Street research that highlights solid recent results, early traction in AI search, and the potential for the company to capture a larger share of pharma marketing budgets, despite ongoing questions about competition and execution risk. Analyst Commentary Street research on Doximity is split, with some bullish analysts pointing to improving execution and AI traction, while more cautious voices focus on execution risk, competition in healthcare AI, and visibility on longer term growth.
Seeking Alpha • Aug 07

Doximity Jumps On Earnings: Explaining The Outsized Stock Move (Rating Upgrade)

Summary Doximity, Inc. is upgraded to buy as the narrative shifts from stagnation to credible reacceleration, driven by AI engagement and improved revenue guidance. Revenue grew 7% YoY to $156.6M, with FY27 guidance raised to $671–681M, while margins compressed due to intentional reinvestment in AI and sales. AI tools, especially Doximity Ask, are rapidly integrating into physician workflows, positioning DOCS for deeper engagement and future monetization opportunities. DOCS stock valuation sits at a discount to peers on earnings and EBITDA, with the upside hinging on AI-driven engagement translating into sustained revenue growth. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 21

DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power

The analyst fair value estimate for Doximity has been reset from $55.00 to $36.89 after multiple firms trimmed price targets, citing concerns about slower core growth, heavier AI investment weighing on margins, and rising competitive and execution risks. Analyst Commentary Recent Street research on Doximity reflects a reset in expectations around growth, profitability, and competitive positioning, particularly as the company leans into heavier AI investment and faces questions about the durability of its core advertising business.
ナラティブ更新 • Jul 07

DOCS: AI Spending And Competitive Pressures Will Test Healthcare Moat And Reengagement Potential

Doximity's analyst price target has been trimmed as fair value and the assumed future P/E move lower, with analysts citing weaker revenue visibility, heavier AI spending, and rising competitive pressures around digital pharma marketing and healthcare AI tools. Analyst Commentary Recent Street research on Doximity points to a more cautious stance, with many firms cutting price targets and revisiting growth expectations after the latest earnings reports and long term guidance.
ナラティブ更新 • Jun 23

DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement

The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.
新しいナラティブ • Jun 13

High physician usership and impressive AI tools

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice.
ナラティブ更新 • Jun 07

DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement

Analyst price targets for Doximity have been reset lower, with the internal fair value estimate moving from $37.77 to $25.15 as analysts factor in slower projected revenue growth, softer profit margins, and a reduced future P/E multiple amid industry wide concerns about digital ad spending, rising competition, and uncertain payoffs from heavier AI investment. Analyst Commentary Street research has turned more cautious on Doximity following its recent results and fiscal 2027 outlook, with many firms cutting price targets and, in several cases, downgrading ratings.
ナラティブ更新 • May 23

DOCS: Heavier AI Spending And Competition Will Drive A Cautious Bearish Outlook

Analysts cut the Doximity fair value estimate from $25.00 to $18.00, citing a wave of price target reductions and ratings downgrades that point to slower expected revenue growth, thinner margins, rising AI investment costs, and tougher digital advertising and healthcare IT competition. Analyst Commentary Street research around Doximity has shifted decisively more cautious, with a cluster of downgrades and lower price targets following the most recent earnings and long term outlook.
ナラティブ更新 • May 09

DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power

Analysts trimmed their Doximity fair value estimate to $55.00 from $56.00, reflecting reduced revenue growth assumptions, partly offset by expectations for slightly higher profit margins and a marginally richer future P/E multiple following a series of recent price target cuts and mixed rating changes across the Street. Analyst Commentary Recent Street research on Doximity has been mixed, with a cluster of price target cuts and rating changes alongside a handful of more constructive views.
ナラティブ更新 • Apr 21

DOCS: Healthcare Moat And AI Tools Will Support Future Engagement

The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.
ナラティブ更新 • Apr 07

DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement

The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
ナラティブ更新 • Mar 24

DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook

Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.
ナラティブ更新 • Mar 09

DOCS: AI Tools And Share Buybacks Will Drive Shares Higher

Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.
ナラティブ更新 • Feb 23

DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook

The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.
ナラティブ更新 • Feb 09

DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher

Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.
分析記事 • Feb 06

Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...
ナラティブ更新 • Jan 26

DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement

Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.
ナラティブ更新 • Jan 11

DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement

Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.
ナラティブ更新 • Dec 26

DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher

We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.
ナラティブ更新 • Dec 12

DOCS: Budget Flush And Ad Shift Will Drive Shares Higher

Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.
分析記事 • Nov 14

Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

The Doximity, Inc. ( NYSE:DOCS ) share price has fared very poorly over the last month, falling by a substantial 26...
ナラティブ更新 • Nov 01

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks

Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.
ナラティブ更新 • Oct 18

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.
ナラティブ更新 • Oct 04

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.
ナラティブ更新 • Sep 13

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.
分析記事 • Sep 02

At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Doximity, Inc. ( NYSE:DOCS ) saw a significant share price rise of 32% in the past couple of months on the NYSE...
分析記事 • Aug 15

We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve

NYSE:DOCS 1 Year Share Price vs Fair Value Explore Doximity's Fair Values from the Community and select yours When...
ナラティブ更新 • Aug 10

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.
分析記事 • Jul 08

Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...
分析記事 • Jun 23

With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
分析記事 • May 17

At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Let's talk about the popular Doximity, Inc. ( NYSE:DOCS ). The company's shares saw significant share price movement...
分析記事 • May 01

Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Doximity fair value estimate is US$54.31 With US$56.88 share...

収支内訳

Doximity の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:DOCS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 26656167235142
31 Mar 26645196222131
31 Dec 25638239215116
30 Sep 25621253207104
30 Jun 2559023519597
31 Mar 2557022319193
31 Dec 2455020118488
30 Sep 2451717417686
30 Jun 2449416117183
31 Mar 2447514817182
31 Dec 2346813816983
30 Sep 2344812316784
30 Jun 2343711916683
31 Mar 2341911316080
31 Dec 2240211915376
30 Sep 2238414114672
30 Jun 2236214813868
31 Mar 2234413312862
31 Dec 2131710711457
30 Sep 212775710153
30 Jun 21243308847
31 Mar 21207227844
31 Dec 20177146740
31 Mar 20116114632
31 Mar 198614027

質の高い収益: DOCSは 高品質の収益 を持っています。

利益率の向上: DOCSの現在の純利益率 (25.5%)は、昨年(39.9%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: DOCSの収益は過去 5 年間で年間20.6%増加しました。

成長の加速: DOCSは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: DOCSは過去 1 年間で収益成長率がマイナス ( -29% ) となったため、 Healthcare Services業界平均 ( 12.4% ) と比較することが困難です。

株主資本利益率

高いROE: DOCSの 自己資本利益率 ( 18.2% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/17 19:21
終値2026/08/14 00:00
収益2026/06/30
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Doximity, Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
Vikram KesavabhotlaBaird
Glen SantangeloBarclays
Nisala WeerasuriyaBerenberg